{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:22Z","timestamp":1791910642893,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the long-term outcome of tacrolimus for childhood-onset myasthenia gravis (CMG) with an inadequate response to glucocorticoids, and investigate factors associated with favorable outcomes following tacrolimus treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, observational cohort study was performed for CMG patients who had not improved satisfactorily after sufficient prednisone therapy for at least 8 weeks. All patients were given tacrolimus in doses of 2\u20133 mg for more than 6 months. The primary efficacy outcome was assessed using the prednisone dose, quantitative MG (QMG), and MG-activity of daily living (ADL) scores. The participants were divided into improved and unimproved groups based on changes in QMG scores to investigate the risk factors that affected tacrolimus efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 149 glucocorticoid resistant CMG patients were finally enrolled in our study, with 113 (75.8%) responding well to tacrolimus (defined as minimal manifestation status or better). One month after initiating tacrolimus, there was a noticeable improvement in prednisone dose, QMG, and ADL scores, which continued to improve throughout the study. More importantly, the prednisone was eventually stopped in 89 of the patients (78.8%). Thymus type [odds ratio (OR) = 3.156, 95% confidence interval (CI) 1.427\u20136.978; <jats:italic>P<\/jats:italic> = 0.005] and pre-intervention status (OR = 0.284, 95%CI 0.109\u20130.741; <jats:italic>P<\/jats:italic> = 0.010) were independent predictors of tacrolimus efficacy after controlling for confounding factors in multiple logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The majority of glucocorticoid-resistant CMG patients have a good long-term prognosis after adding tacrolimus. Thymus type and pre-intervention status can serve as potential predictors affecting the efficacy of tacrolimus.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.820205","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T04:46:47Z","timestamp":1644295607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhuajin","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengcui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.25267","article-title":"Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis","volume":"84","author":"He","year":"2018","journal-title":"Ann Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/jnnp.2006.100545","article-title":"Clinical and serological study of myasthenia gravis in HuBei Province, China","volume":"78","author":"Zhang","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui","year":"2015","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of oral steroid therapy for Myasthenia Gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.expneurol.2018.11.006","article-title":"Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients","volume":"312","author":"Li","year":"2019","journal-title":"Exp Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1016\/S0021-9258(18)53220-8","article-title":"Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin","volume":"268","author":"Ning","year":"1993","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.braindev.2012.06.012","article-title":"Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus","volume":"35","author":"Mori","year":"2013","journal-title":"Brain Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.braindev.2006.02.001","article-title":"Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus","volume":"28","author":"Kakisaka","year":"2006","journal-title":"Brain Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ctim.2014.08.003","article-title":"The clinical absolute and relative scoring system-a quantitative scale measuring myasthenia gravis severity and outcome used in the traditional Chinese medicine","volume":"22","author":"Liu","year":"2014","journal-title":"Complement Ther Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcpt.12914","article-title":"Prediction of drug-drug interaction between tacrolimus and principal ingredients of wuzhi capsule in chinese healthy volunteers using physiologically-based pharmacokinetic modelling","volume":"122","author":"Zhang","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","article-title":"Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki A","year":"2000","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000347068","article-title":"Tacrolimus monotherapy: a promising option for ocular myasthenia gravis","volume":"69","author":"Yagi","year":"2013","journal-title":"Eur Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in Southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/WCO.0b013e32833c32af","article-title":"Acquired myasthenia gravis in childhood","volume":"23","author":"Evoli","year":"2010","journal-title":"Curr Opin Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00415-017-8478-z","article-title":"Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms","volume":"264","author":"Hong","year":"2017","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"26263","DOI":"10.1074\/jbc.M114.582882","article-title":"NF-\u03baB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity","volume":"289","author":"Erlejman","year":"2014","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7499\/j.issn.1008-8830.2004215","article-title":"Clinical effect of tacrolimus in the treatment of myasthenia gravis in children","volume":"22","author":"Li","year":"2020","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi."},{"key":"B32","doi-asserted-by":"publisher","first-page":"594152","DOI":"10.3389\/fneur.2020.594152","article-title":"Favorable effects of tacrolimus monotherapy on myasthenia gravis patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00595-012-0318-2","article-title":"Thymus, thymoma and myasthenia gravis","volume":"43","author":"Fujii","year":"2013","journal-title":"Surg Today."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/ene.14039","article-title":"Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis","volume":"27","author":"Nishida","year":"2020","journal-title":"Eur J Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.820205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T04:46:51Z","timestamp":1644295611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.820205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.820205"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.820205","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"article-number":"820205"}}